Alberto Auricchio, PhD is Coordinator of the Molecular Therapy Program at TIGEM and Professor of Medical Genetics at University “Federico II” in Naples, Italy.

He is co-author of over 140 peer-reviewed publications and inventor of several patents related to the use of viral vectors for gene therapy.

Dr Auricchio is Executive Board Member of the European Society of Gene and Cell Therapy and acts as Scientific Advisory Board member of several gene therapy companies (Odylia, Gyroscope, Alia Therapeutics, Innovavector).

Prior to AAVantgarde he contributed to the development of Luxturna, the first approved gene therapy for an ocular disease and has developed AAV-based gene therapy for a rare lysosomal storage disease from discovery up to first-in-human (the first in vivo gene therapy clinical trial in Italy).